New Plu­vic­to da­ta point to a po­ten­tial wider in­di­ca­tion, but No­var­tis leaves reg­u­la­to­ry time­line up in the air: #ES­MO23

MADRID — No­var­tis’ ra­dio­phar­ma­ceu­ti­cal drug Plu­vic­to staved off prostate can­cer pro­gres­sion for a me­di­an of six months longer than hor­mone ther­a­py in a piv­otal study, open­ing up the pos­si­bil­i­ty of the drug as an ear­li­er treat­ment op­tion.

The Phase III study, known as PS­MAfore, in­clud­ed 468 prostate can­cer pa­tients who had pre­vi­ous­ly re­ceived one an­dro­gen re­cep­tor ther­a­py but not chemother­a­py. Those who re­ceived Plu­vic­to lived for a me­di­an of 12 months be­fore their dis­ease pro­gressed com­pared to a me­di­an of 5.6 months for those who re­ceived an­dro­gen re­cep­tor ther­a­py — ei­ther Zyti­ga or Xtan­di.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER